CluenexPfizer Inc PFE
Pfizer Inc scores average on business quality (4.6 of 10). Here is why, in plain words, and what our sealed record shows.
Why it matters
- What Pfizer Inc does
Pfizer makes money by discovering, developing, and selling biopharmaceutical products and vaccines globally, charging hospitals, pharmacies, and payers for therapeutics across oncology, rare disease, and immunology.
- What it does best
Pfizer leverages massive commercial scale and distribution reach to quickly commercialize late-stage clinical assets globally. Its gross margin sits at 74.7%, beating JNJ's 68.1% and topping three-quarters of its healthcare sector peers.
- The main risk
Pandemic product demand contraction and patent cliffs on legacy blockbusters threaten high-margin revenue streams. Without faster organic pipeline uptake, cash generation risks remaining compressed near current levels.
Quality, check by check
Scored against its own industry, from company filings.
Gross margin sits at 74.7% and operating margin at 31.4%, though net margin is compressed at 6.8%. ROE of 4.9% reflects lower post-pandemic earnings power, showing profitability softens significantly as pandemic revenue recedes.
Scale and global distribution form a moderate moat locking in major healthcare providers and regulatory relationships. Operating margin sits in the sector's 84th percentile, though intense generic competition limits pricing power.
Revenue declined 1.6% over the latest period, sitting in the bottom decile of its sector at the 6th percentile. Growth has stalled significantly compared to the 2022 pandemic peak, showing no clear near-term acceleration.
Debt-to-equity of 0.7x and interest coverage of 7.4x mean obligations are manageable. Free cash flow reached $11.0B, though the balance sheet remains weighed down by $51.2B in net debt, leaving the financial foundation mixed.
Insiders
Executives and directors, from SEC Form 4 filings we read ourselves. Open market trades only; grants, option exercises and pre-planned sales left out.
3 insiders bought $3.0M on the open market. 1 sold $83K outside pre-planned sales.
Our sealed record on PFE
Verdicts appear here 30 days after we publish them; members see today's. Each one is in the nightly ledger, fingerprinted the night it was made.
The first sealed verdicts appear here on Oct 11, 2026.
Questions
Pfizer Inc scores average on the Cluenex quality check (4.6 of 10), measured against its own industry. Profitability is fair, moat fair, growth slow and financial health fair.
In the last 90 days of SEC Form 4 filings: 3 insiders bought $3.0M on the open market. 1 sold $83K outside pre-planned sales.
Nov 3, 2026.
See PFE today
- Today's verdict on PFE, and why
- Fair value with cautious, base and optimistic cases
- The exact price that would change the verdict
- Which stocks each signal names, the night it fires
Cite this page: Cluenex, “Pfizer Inc (PFE)”, https://cluenex.com/stocks/pfe/, data as of Oct 10, 2026.